Psychstuff A survival guide for clinical psychiatry
Psychiatric Times Feed
- Behind the Steering Wheel of Your Brain: Residual Negative and Cognitive Symptoms in Schizophrenia 04/01/2025Treatments that target negative and cognitive symptoms of schizophrenia could put patients in better control of their life.
- New NDA Submitted: Bysanti to Treat Acute Bipolar I and Schizophrenia 04/01/2025Vanda Pharmaceuticals has submitted an NDA for approval of Bysanti for the treatment of acute bipolar I disorder and schizophrenia.
- LB-102: A New, Novel Drug for Schizophrenia 04/01/2025John Kane, MD, shares why you should be paying attention to LB-102 for the treatment of schizophrenia.
- Standing Up Against Hate: Let’s Be Foolish 04/01/2025Here’s how we can best stand up to hatred…
- Presenting Our April Theme: Sleep 04/01/2025Do you want to be featured in a future Special Report? Check out our April theme!
- SPG302: A Synaptic Regenerative Treatment Option for Schizophrenia 03/31/2025A schizophrenia research expert weighs in on the recent announcement concerning SPG302 for the treatment of individuals with schizophrenia.
- The Psychiatric Pipeline in Review: Quarter 1, 2025 03/31/2025What percentage of 2025 psychiatric pipeline news was positive vs negative? What disease states are most prominently featured in recent research? Learn more in this exclusive article.
- Additional Positive Data on LB-102 for the Treatment of Acutely Exacerbated Schizophrenia 03/31/2025LB Pharmaceuticals presented additional positive data from NOVA1 exploring LB-102 in patients with acutely exacerbated schizophrenia, at the 2025 Annual Congress of the Schizophrenia International Research Society.
- Phase 2 Trial Open Enrollment for SPG302, First Synaptic Regenerative Approach to Treat Schizophrenia 03/31/2025Spinogenix announced open enrollment for the phase 2 trial of SPG302, the first synaptic regenerative approach to treat schizophrenia with the potential to improve outcomes across all symptom domains.
- It Was National Doctors’ Day and a Top Vaccine Expert Resigned 03/31/2025Yesterday marked a somber National Doctors’ Day…
- LB-102 for the Treatment of Acutely Exacerbated Schizophrenia: Insights From the Principal Investigator 03/31/2025In this exclusive interview with Psychiatric Times, John Kane, MD, shares more on the new positive data on LB-102 for the treatment of acutely exacerbated schizophrenia.
- Celebrating World Bipolar Day 2025: Best Practices in Treating Bipolar Disorder 03/30/2025In honor of World Bipolar Day, our Mood Disorders Section Editor shares his favorite clinical pearls for treating bipolar disorder.
- The Week in Review: March 24-28 03/28/2025Here are highlights from this week in Psychiatric Times, including positive clinical trial news for an ADHD treatment and an exclusive interview on the joint statement defending psychotropic medication safety.
- Post-Acute Sequelae of COVID-19 Infection Presenting With Neuropsychiatric Symptoms: Diagnosis and Management 03/28/2025In this CME article, learn more about the common neuropsychiatric sequelae of post-acute sequelae of COVID-19, the underlying neurobiological mechanisms, and evidence-based treatments and interventions.
- Leveling Up Together: Nurturing LGBTQIA+ Mental Health in Gaming Communities 03/28/2025The LGBTQIA+ community has faced marginalization and stereotyping in media, including video games. Let’s examine the intersection of identity, mental health, and video gaming.
- As Capitalism Gasps for Breath I Watch the Knicks Game 03/28/2025"Was this what Rome felt like toward the end? When the colosseums filled with gladiators stirred the masses into a frenzy."
- Get Ready for Psyched Perspectives 03/27/2025Get ready for our new video series, "Psyched Perspectives"!
- The Humanist Who Writes About Religion: A Relational Dialogue With H. Steven Moffic, MD 03/27/2025A social psychiatrist who stays on the ethical way.
- In Schizophrenia, Nicotine Enhances Cognitive Performance by Improving Brain Network Function 03/27/2025The prevalence of tobacco use in schizophrenia is over 60%—3 times that of the general population. However, the reason for the high prevalence of tobacco use in schizophrenia remains largely unknown.
- Postpartum: The Reality vs The Idealized Narrative 03/27/2025Motherhood: what is truth vs idealized narrative?
Psychiatric News Feed
- An error has occurred, which probably means the feed is down. Try again later.
Example Widget 1 - One COl
Flickr
Advertisement
